It has been about a month since the last earnings report for BioDelivery Sciences International, Inc. . Shares have lost about 15% in that time frame, underperforming the market.
Will the recent negative trend continue leading up to the stock's next earnings release, or is it due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
BioDelivery Fourth Quarter Loss Wider Than Expected; Sales Meet
BioDelivery Sciences reported loss of $0.29 per share in the fourth quarter of 2016, slightly wider than the Zacks Consensus Estimate of a loss of $0.28. The company had reported earnings of $0.19 per share in the year-ago quarter.
Revenues, on the other hand, were $3.9 million in the reported quarter compared with $32.2 million a year ago. This deterioration can mainly be attributed to a one-time milestone payment received from Endo International in 2015 related to approval of Belbuca. However, revenues were in line with the Zacks Consensus Estimate.
Quarter in Detail
Bunavail, recorded a 33.3% year-over-year increase in sales to $2 million. Prescription sales of the drug increased 4% year over year in the fourth quarter.
In the fourth quarter, research and development expenses amounted to $5.1 million, flat with the year-ago level. Selling, general and administrative expenses were down 18.8% year over year to $6.4 million.
2016 Results
Full-year revenues were $15.5 million compared with the year-ago figure of $48.2 million. Revenues were almost in line with the Zacks Consensus Estimate.
The full-year loss of $1.25 per share was in line with the Zacks Consensus Estimate. The company had incurred a loss of $0.72 per share a year ago.
How Have Estimates Been Moving Since Then?
Following the release, investors have witnessed an upward trend in fresh estimates. There have been four revisions higher for the current quarter In the past month.
VGM Scores
At this time, BioDelivery's stock has a great score of 'A' on grade and momentum front. However, the stock was allocated a grade of 'F' on the value side, putting it in the lowest quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of 'B'. If you aren't focused on one strategy, this score is the one you should be interested in.
Zacks' style scores indicate that the company's stock is suitable for growth and momentum investors.
Outlook
Estimates have been trending upward for the stock. The magnitude of these revisions also looks promising. Interestingly, the stock has a Zacks Rank #3 (Hold). We are expecting an inline return from the stock in the next few months.
Image: Bigstock
BioDelivery (BDSI) Down 15% Since Earnings Report: Can It Rebound?
It has been about a month since the last earnings report for BioDelivery Sciences International, Inc. . Shares have lost about 15% in that time frame, underperforming the market.
Will the recent negative trend continue leading up to the stock's next earnings release, or is it due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
BioDelivery Fourth Quarter Loss Wider Than Expected; Sales Meet
BioDelivery Sciences reported loss of $0.29 per share in the fourth quarter of 2016, slightly wider than the Zacks Consensus Estimate of a loss of $0.28. The company had reported earnings of $0.19 per share in the year-ago quarter.
Revenues, on the other hand, were $3.9 million in the reported quarter compared with $32.2 million a year ago. This deterioration can mainly be attributed to a one-time milestone payment received from Endo International in 2015 related to approval of Belbuca. However, revenues were in line with the Zacks Consensus Estimate.
Quarter in Detail
Bunavail, recorded a 33.3% year-over-year increase in sales to $2 million. Prescription sales of the drug increased 4% year over year in the fourth quarter.
In the fourth quarter, research and development expenses amounted to $5.1 million, flat with the year-ago level. Selling, general and administrative expenses were down 18.8% year over year to $6.4 million.
2016 Results
Full-year revenues were $15.5 million compared with the year-ago figure of $48.2 million. Revenues were almost in line with the Zacks Consensus Estimate.
The full-year loss of $1.25 per share was in line with the Zacks Consensus Estimate. The company had incurred a loss of $0.72 per share a year ago.
How Have Estimates Been Moving Since Then?
Following the release, investors have witnessed an upward trend in fresh estimates. There have been four revisions higher for the current quarter In the past month.
BioDelivery Sciences International, Inc. Price and Consensus
BioDelivery Sciences International, Inc. Price and Consensus | BioDelivery Sciences International, Inc. Quote
VGM Scores
At this time, BioDelivery's stock has a great score of 'A' on grade and momentum front. However, the stock was allocated a grade of 'F' on the value side, putting it in the lowest quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of 'B'. If you aren't focused on one strategy, this score is the one you should be interested in.
Zacks' style scores indicate that the company's stock is suitable for growth and momentum investors.
Outlook
Estimates have been trending upward for the stock. The magnitude of these revisions also looks promising. Interestingly, the stock has a Zacks Rank #3 (Hold). We are expecting an inline return from the stock in the next few months.